



Meda's new share issue oversubscribed

- 41,628,926 shares, corresponding to 99.61 per cent of the offered shares, have been subscribed through exercise of subscription rights
- Including the shares that have been subscribed for without preferential rights, the rights issue has been oversubscribed by approximately 14 per cent
- The issue generated SEK 2,508 million before issue costs

Calculation of Meda's new issue revealed that 41,628,926 shares, corresponding to 99.61 per cent of the offered shares, have been subscribed through exercise of subscription rights. Including the shares that have been subscribed for without preferential rights, the rights issue has been oversubscribed by approximately 14 per cent. The issue generated SEK 2,508 million, before issue costs.

The 162,817 shares that have not been subscribed for through exercise of subscription rights, corresponding to 0.39 per cent of the total number of offered shares, will be allotted to those shareholders who subscribed for shares without preferential rights in accordance with principles set forth in the prospectus.

Through the rights issue the number of shares in Meda increases by 41,791,743 shares and the share capital increases by 83,583,486 SEK. After the rights issue the total number of shares in Meda amount to 104,479,358 shares and the share capital to 208,958,716 SEK. The last trading day with the paid-up subscribed shares (BTA) is expected to be 9 December 2005. The newly issued shares are expected to be traded on the O-list of the Stockholm Stock Exchange (Stockholmsbörsen) starting Monday 19 December, 2005.

"The acquisition of Viatris positions Meda as a leading European specialty pharma company. It is very gratifying that the company's shareholders have confidence in our further build-up." says Anders Lönner, CEO of Meda.

Enskilda Securities is acting as financial advisor to Meda AB for the rights issue.

Solna, Sweden, 29 November 2005

Meda AB (publ)

For more information, please contact:

Anders Lönner, CEO Meda, +46 (0)8 630 19 00

Anders Larnholt, Investor Relations, +46 (0)8 630 19 62

MEDA AB (publ) – the Swedish specialty pharmaceutical company. Meda markets prescription and over-the-counter drugs and med-tech solutions. The company is listed on the Stockholm stock exchange's (Stockholmsbörsen) Attract 40 list.